$AZ

A2Z Cust2Mate Solutions Corp. (AZ) Reports Q2 Loss, Beats Revenue Estimates

A2Z Cust2Mate Solutions Corp. (AZ) reported Q2 adjusted EPS loss of $0.16, matching the Zacks Consensus Estimate, versus a $0.31 loss a year earlier. Revenue rose to $5.9M for the quarter ended June 2026, beating consensus by 73.65% and up from $1.16M a year ago. Consensus for next quarter is -$0.09 EPS on $8.7M revenue.

Original reporting
Published Aug 12, 2026, 9:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 12:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$AZ
Neutral
medium confidence
Mentioned
$AZ
Relevance
6/10
alphai data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$AZNeutralMed
01

Why it matters

Q2 shows a large revenue beat but continued adjusted EPS losses, so the key trading variable is whether management commentary shifts near-term EPS expectations and estimate revisions from the current mixed trend.

02

Market read

This is a company-specific earnings update with a revenue upside but no EPS improvement, making the next catalyst the earnings call and any subsequent estimate revisions.

03

What to watch

The article notes mixed estimate revisions and a Hold (Zacks Rank #3); traders should focus on whether the earnings call changes the coming-quarter and FY consensus trajectory.

Relevance 6/10Novelty 6/10Timing: after-hours/next-session reaction to newly released Q2 results and earnings-call commentary

Background

The piece summarizes A2Z Cust2Mate Solutions’ Q2 results versus consensus and discusses the earnings-outlook framework (estimate revisions, Zacks Rank).

Company-level read

Ticker impact

$AZNeutralMedium confidence
Context

A2Z Cust2Mate Solutions reported Q2 adjusted EPS of -$0.16 and revenues of $5.9M, beating revenue estimates by 73.65%.

Expected impact

Likely choppy/mean-reverting unless the earnings call meaningfully changes near-term EPS and revenue outlook.

Evidence & confidence

The article provides hard Q2 results (EPS in line, revenue beat) but no new guidance numbers; it flags that stock follow-through depends on management commentary and upcoming estimate revisions.

Market effects

Limited direct read-through, but reinforces that small-cap internet/software names can see revenue volatility without EPS inflection.

No specific regional spillover described.

No global macro or cross-border catalyst mentioned.

Counterpoint

Revenue beat may not translate into durable profitability if losses persist and future consensus remains negative.

Key entities

  • A2Z Cust2Mate Solutions Corp.

    Reported Q2 adjusted EPS of -$0.16 and revenues of $5.9M, with revenue beating consensus by 73.65%.

  • Zacks Consensus Estimate

    Used as the comparison point for EPS and revenue beats/misses in the article.

  • Zacks Rank #3 (Hold)

    The article states the stock is expected to perform in line with the market near term based on the current rank.

Related articles

$AZMedAI 8/10

A2Z Reports Second Quarter 2026 Revenue of $5.9 Million

A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) reported Q2 2026 revenue of $5.9 million, up from $1.2 million, with Smart Cart revenue of $4.41 million. Gross profit rose to $2.5 million and gross margin to 42.6%. Net loss was $7.3 million. The company cited a $30 million credit line with Bank Leumi and expects $25 million in H2 smart cart revenue.

$AZMedAI 8/10

Allianz enters deal to acquire UOB asset management arm

Allianz Global Investors agreed to acquire UOB Asset Management for S$555m (US$432.7m), covering UOBAM operations in eight Asian markets. UOB and AGI will also form a distribution partnership. UOB expects a pre-tax gain of about S$330m and a CET ratio lift of 14 bps, subject to regulatory approval, with closing in 2027.

$AZMedAI 8/10

Pathos AI signs two cancer deals with Alphamab and AZ

Pathos AI said it licensed Alphamab’s bispecific ADC JSKN016 for solid tumors outside Greater China in a deal worth up to $2.2 billion, including $125 million upfront, up to $2.09 billion in milestones and royalties. JSKN016 targets TROP2 and HER3 and is in Phase 3 for TNBC. Pathos also partnered with AstraZeneca on AZD4241, an ER-targeting PROTAC in preclinical testing for HR-positive, HER2-negative breast cancer.

$AZMed

Allianz Asia Holding Pte. Ltd. agreed to acquire HSBC Life Pte. Ltd. from HSBC Holdings plc for SGD 2.7 billion.

Allianz Asia Holding Pte. Ltd. agreed to acquire HSBC Life (Singapore) Pte. Ltd. from HSBC Holdings plc for SGD 2.7 billion, including SGD 2.7 billion allocated to HSBC Life’s common equity. The deal is subject to regulatory approval, with expected completion between Jan 1 and Jun 30, 2027. HSBC Life reported EBIT of SGD 118.1 million for 2025.